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Neuroleptic malignant syndrome 
(NMS) is one of the rave but potentially 
fatal, idiosyncratic reaction to Neurolep-
tics and other medications (Smego and 
Durack, 1985). It is characterised by 
fever, autonomic dysfunction, rigidity, 
altered conscious state with associated 
laboratory parameters like raised GPK, 
LDH, Hepatic enzymes, leucocytosis. 
This syndrome was first described by 
Delay and Deniker in 1968. Since 1980 
about 50 cases have appeared in British 
and French literature (Coonset al, 1982; 
Goekoop and Garbaat, 1982). A psychia-
trist must be aware of this syndrome 
wich may be many times under diagno-
sed. 
Recently we have successfully treated 
two cases of Neuroleptic Malignant 
Syndrome. 
Case Reports 
Case I. : Miss. R., a 14 year old girl was 
admitted at the J.J. Hospital, with 
Schizophrenia. Patients was given injec-
tion haloperidol 5mg. intramuscularly and 
received 3 more injections of the Same on 
the following day. 
Approximately 36 hrs. following the 
Hist injection, she was found to have 
high grade fever- Soon thereafter, she was 
found to be mute, rigid, catatonic and 
was given injection Benzatropinc 2 mg. 
i.m.. but she did not respond. At this 
stage a lumbar puncture was done, 
patient's GSF was normal. Patient's EEG 
was also normal. 
Next day, she started having fluctua-
ting BP varying from 160/120 to 120/80. 
Her temperature fluctuated between 99°F 
and 104°F. She had excessive sweating, 
tachycardia, rigidity and altered consci-
ous stage. At this stage a diagnosis of 
NMS was considered and the following 
investigations were carried out. 
Patients WBG count was 14500 mm
8. 
GPK 2270 MU., LDH 321 IU., 
SGOT 120 units/ml., SGPT 60 units/ml. 
Her S. electrolyte., S. creatinine., 
Blood Urea., Blood Sugar., X-ray chest., 
Urine-exam were within normal limits. 
Patient was treated with I.V. fluids and 
tepid sponging and other supportive care. 
Within 4-5 days patient started showing 
improvement and by 15th day of admi-
ssion patient had improved completely 
from NMS. No specific treatment in the 
form of Dantrolene Bromocryptine was 
given. After resolution of NMS her psy-
chotic features persisted. 
Patient was treated with EGTs under 
I.V. Diazepam and was not given any 
neuroleptics. Her psychotic features 
improved by 8th ECT and she was dis-
charged by 6th week of her admission and 
she is under regular follow up. 
Case 2-
Mrs. M. a 24 year female presented 
with schizophrenia. She was started on 
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oral haloperidol 5 mg. tds. She did not 
show much improvement. She was also 
given inj. haloperidol 5 mg/im. on four 
occasions. 
She was then admitted in a hospital. 
She did not show much improvement on 
OPD treatment. 
On day of admission, patient develo-
ped temperature of 100.4°F. No cause 
for fever could be detected clinically at 
this stage. On 3rd day of admission 
patient had temperature of 103°F with 
neck rigidity but without Kernig's sign. 
Investigations of G. B. C, Urine, X-ray 
chest, G.S.F., were normal. Next day 
patient's fever fluctuated between 100-4°F 
to 103°F. She also had altered sensorium, 
and mutism, catatonic posture, sweating, 
rigidity and tachycardia. Her BP remained 
normal. 
At this stage a diagnosis of NMS was 
entertained and further investigations 
showed. CBC.-WNL., CPK-2000 MU. 
LDH-780 IU, SGOT-1250 units/ml, 
SGPT-400 units/ml, S. creatinine-1.85 
mEq/lit Neuroleptics were discontinued. 
A general supportive care was given which 
included tepid sponging, I.V. fluids etc. 
This patient too was not given any specific 
treatment in the form of Dantrolene and 
Bromocryptine. By 5th day of her admis-
sion her temperature had subsided, 
patient became alert; started taking 
orally. Following improvement from NMS 
her psychotic features became prominent 
and she was started on ECTs. Patients 
blood tests were repeated after I week. 
Her SGOT and SGPT were 300 units/ml 
and 200 units/ml respectively. 
Her psychotic features remitted on 
ECTs and she was discharged without 
medication. However, within 15 days 
of discharge patient had relapsed. Hence 
patient was put on oral Trifluperazine 
and till now patient is being < followed 
up on the same without recurrence of 
NMS. 
COMMENTS : 
Important differential diagnosis in 
these cases would have been malignant 
hyperthermia, Neuroloptic induced heat 
stroke, acute lethal catatonia, CNS infec-
tions and toxic encepalopathy (Levenson, 
1985). Malignant hyperthermia though 
clinically indistinguishable from NMS 
usually follows i.v. Succinylcholine and 
inhalational anasthetics. Heat stroke is 
distinguished from NMS by absence of 
rigidity and sweating. NMS, though 
clinically indistinguishable from lethal 
catatonia, usually follows neuroleptics 
and other drug administration. Acute 
dystonic reaction can be distinguished 
from NMS by absence of fever and 
Leucocytosis (Levenson, 1985). 
Cases have been reported in literature 
where NMS were treated with Dantro-
lene, Bromocriptine and Amantidine 
(Levenson, 1985). However, they have 
not been shown to be clearly and consis-
tently superior to other supportive inter-
vention. At present, there is no clear 
evidence of the value of any specific 
treatment (Levenson, 1985). In view of 
this, both patients were treated with 
supportive care only. Gases have appeared 
in the literature where NMS recurred 
following reintroduction of neuroleptics 
(Levenson, 1985). In view of this poten-
tial risk, patients were treated with ECTs 
and diazepam. Both patients showed 
progressive improvement and their 
psychosis remitted completely. 
Since both had Schizophreniform 
psychosis with good prognostic features, 
neuroleptics were not continued and they 
were advised to follow up at regular inter-
vals. However, since the 2nd patient had 
a relapse after 15 days, she had to be 
started on tab. Trifluperazine again. 
Starting the patient on tab. Trifluperazine 
did not cause a recurrence of NMS, indi-
cating that reintroduction of a different 
group of antipsychotic, particularly in a 92  D. K. DESMUKH et al. 
non-injectable form, may not produce a 
recurrence of NMS. 
This can bo explained by the fact 
that NMS being an idiosyncratic reaction 
can occur in a patient who is susceptible 
to one group of antipsychotics and not to 
.mother. The antipsychotic should 
preferably be in an oral form is only a 
conjecture and more cases arc to be 
studied in order to form a conclusive 
opinion. 
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